| Characteristics and Outcomes of Patients With Relapsed/Refractory Multiple Myeloma After Exposure to Lenalidomide in First Line of Therapy: A Single Center Database Review in … E Kastritis, I Ntanasis-Stathopoulos, F Theodorakakou, M Migkou, ... Clinical Lymphoma Myeloma and Leukemia 24 (7), 468-477, 2024 | | 2024 |
| Evaluation of a novel method to guide belantamab mafodotin dosing in multiple myeloma based on a patient-reported questionnaire. E Terpos, M Gavriatopoulou, I Ntanasis-Stathopoulos, P Malandrakis, ... Journal of Clinical Oncology 42 (16_suppl), 7530-7530, 2024 | | 2024 |
| The Interplay between the DNA Damage Response (DDR) Network and the Mitogen-Activated Protein Kinase (MAPK) Signaling Pathway in Multiple Myeloma P Malamos, C Papanikolaou, M Gavriatopoulou, MA Dimopoulos, ... Preprints, 2024 | | 2024 |
| Characteristics of Orthodontic Treatment in Cancer Survivors: A Systematic Review N Karvelas, I Ntanasis-Stathopoulos, MA Makrygiannakis, ... Journal of Clinical Medicine 13 (10), 2858, 2024 | | 2024 |
| Implications and hidden toxicity of cardiometabolic syndrome and early‐stage heart failure in carfilzomib‐induced cardiotoxicity P Efentakis, A Varela, S Lamprou, ED Papanagnou, M Chatzistefanou, ... British Journal of Pharmacology, 2024 | | 2024 |
| Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin P Efentakis, A Choustoulaki, G Kwiatkowski, A Varela, IV Kostopoulos, ... Basic Research in Cardiology, 1-24, 2024 | 1 | 2024 |
| Retinopathy in a Patient With IgM MGUS: Causal Association or an Epiphenomenon? I Ntanasis-Stathopoulos, E Kastritis, J Tzartos, E Terpos, MA Dimopoulos, ... In Vivo 38 (2), 954-957, 2024 | | 2024 |
| Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated … M Gavriatopoulou, I Ntanasis-Stathopoulos, P Malandrakis, D Fotiou, ... American journal of hematology 99 (3), 502-504, 2024 | | 2024 |
| A rare case of TEMPI syndrome (telangiectasias, erythrocytosis, monoclonal gammopathy and ascites) associated with IgM monoclonal gammopathy S Asimakopoulou, P Malandrakis, A Kamiliou, M Gavriatopoulou, K Bafa, ... Leukemia & Lymphoma, 1-3, 2024 | | 2024 |
| Small RNA‐seq and clinical evaluation of tRNA‐derived fragments in multiple myeloma: Loss of mitochondrial i‐tRFHisGTG results in patients' poor treatment … K Soureas, MA Papadimitriou, P Malandrakis, AM Papanota, ... British Journal of Haematology, 2024 | | 2024 |
| Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma IV Kostopoulos, I Ntanasis‐Stathopoulos, P Rousakis, P Malandrakis, ... American Journal of Hematology, 2024 | | 2024 |
| Cardiovascular complications of ribociclib in breast cancer patients O Fiste, E Mavrothalassitis, K Apostolidou, C Trika, M Liontos, ... Critical Reviews in Oncology/Hematology, 104296, 2024 | | 2024 |
| Thrombotic and bleeding complications in patients with AL amyloidosis D Fotiou, F Theodorakakou, S Spiliopoulou, M Gavriatopoulou, M Migkou, ... British Journal of Haematology, 2024 | | 2024 |
| Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic … IV Kostopoulos, D Fotiou, M Gavriatopoulou, P Rousakis, ... Blood Cancer Journal 14 (1), 26, 2024 | | 2024 |
| A 74-Year-Old Man With Waldenström Macroglobulinemia and Progressive Dyspnea V Tzilas, AG Nicholson, M Gavriatopoulou, I Ntanasis-Stathopoulos, ... Chest 165 (2), e39-e43, 2024 | | 2024 |
| Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA E Terpos, I Ntanasis‐Stathopoulos, M Gavriatopoulou, E Katodritou, ... American Journal of Hematology, 2024 | 1 | 2024 |
| ciRS‐7 circular RNA overexpression in plasma cells is a promising molecular biomarker of unfavorable prognosis in multiple myeloma M Papatsirou, CK Kontos, I Ntanasis‐Stathopoulos, P Malandrakis, ... eJHaem, 2024 | | 2024 |
| Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients M Papatsirou, CK Kontos, I Ntanasis‐Stathopoulos, P Malandrakis, ... HemaSphere 8 (1), e34, 2024 | 1 | 2024 |
| Long-term Survival in a Patient With Transformation of Waldenström’s Macroglobulinemia into DLBCL E Solia, I Ntanasis-Stathopoulos, E Kastritis, E Terpos, MA Dimopoulos, ... Cancer Diagnosis & Prognosis 4 (1), 77, 2024 | | 2024 |
| Monoclonal Gammopathy of Undetermined Cardiovascular Significance; Current Evidence and Novel Insights A Tentolouris, I Ntanasis-Stathopoulos, M Gavriatopoulou, I Andreadou, ... Journal of Cardiovascular Development and Disease 10 (12), 484, 2023 | 1 | 2023 |
